Related Experiment Video
Updated: Apr 1, 2026
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors
Daniela Passeri1, Emidio Camaioni2, Paride Liscio1
1TES Pharma S.r.l., via Palmiro Togliatti 20, 06073 Corciano, Perugia, Italy.
Abstract:
Recent years have witnessed a renewed interest in PARP-1 inhibitors as promising anticancer agents with multifaceted functions. Particularly exciting developments include the approval of olaparib (Lynparza) for the treatment of refractory ovarian cancer in patients with BRCA1/2 mutations, and the increasing understanding of the polypharmacology of PARP-1 inhibitors. The aim of this review article is to provide the reader with a comprehensive overview of the distinct levels of the polypharmacology of PARP-1 inhibitors, including 1) inter-family polypharmacology, 2) intra-family polypharmacology, and 3) multi-signaling polypharmacology. Progress made in gaining insight into the molecular basis of these multiple target-independent and target-dependent activities of PARP-1 inhibitors are discussed, with an outlook on the potential impact that a better understanding of polypharmacology may have in aiding the explanation as to why some drug candidates work better than others in clinical settings, albeit acting on the same target with similar inhibitory potency.
Insights
Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors show promise in cancer treatment. Understanding their complex polypharmacology, including interactions across and within families and multi-signaling pathways, is key to optimizing their clinical efficacy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- PARP-1 inhibitors are gaining traction as anticancer agents.
- Olaparib's approval for BRCA1/2 mutated ovarian cancer highlights their potential.
- Understanding PARP-1 inhibitor polypharmacology is crucial for drug development.
Purpose of the Study:
- To provide a comprehensive overview of PARP-1 inhibitor polypharmacology.
- To explore inter-family, intra-family, and multi-signaling polypharmacology.
- To discuss the molecular basis of these activities and their clinical implications.
Main Methods:
- Literature review of PARP-1 inhibitor research.
- Analysis of polypharmacology at distinct levels.
- Discussion of molecular mechanisms and clinical relevance.
Main Results:
- Detailed examination of inter-family polypharmacology.
- Exploration of intra-family polypharmacology.
- Analysis of multi-signaling polypharmacology and its molecular underpinnings.
Conclusions:
- A deeper understanding of PARP-1 inhibitor polypharmacology can explain differential clinical outcomes.
- This knowledge may guide the development of more effective anticancer therapies.
- Further research into polypharmacology is essential for precision oncology.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:02Long-patch Base Excision Repair
01:29Pharmacogenomics: Identification of New Drug Targets
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:42Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...